Additional anti-CD20 antibody therapeutics under development include: obinutuzumab for SLE, rituximab for myalgic encephalomyelitis, ocaratuzumab for follicular lymphoma and RA, ocrelizumab for multiple sclerosis (RA discontinued in 2010), TRU-015 (by Trubion) (discontinued in 2010), IMMU-106 (veltuzumab) for non-Hodgkin’s lymphoma or (2015) immune thrombocytopenia. The gene discussed is MS4A1; the disease is rheumatoid arthritis.